Evidence map›Paper›PMID 38671379›Full record

ArticleBMC pediatrics2024

Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study.

Rachel P Ogilvie, J Bradley Layton, Patricia C Lloyd, Yixin Jiao, Djeneba Audrey Djibo, Hui Lee Wong, Joann F Gruber, Ron Parambi, Jie Deng, Michael Miller and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 6 institutions in 1 country.

Rachel P OgilvieOptum Epidemiology, Boston, MA, USA.
J Bradley LaytonRTI Health Solutions, 3040 East Cornwallis Rd, PO Box 12194, Research Triangle Park, NC, 27709, USA. jblayton@rti.org.
Patricia C LloydUS Food and Drug Administration, Silver Spring, MD, USA.
Yixin JiaoAcumen, LLC, Burlingame, CA, USA.
Djeneba Audrey DjiboCVS Health, Blue Bell, PA, USA.
Hui Lee WongUS Food and Drug Administration, Silver Spring, MD, USA.
Joann F GruberUS Food and Drug Administration, Silver Spring, MD, USA.
Ron ParambiOptum Epidemiology, Boston, MA, USA.
Jie DengOptum Epidemiology, Boston, MA, USA.
Michael MillerOptum Epidemiology, Boston, MA, USA.
Jennifer SongOptum Epidemiology, Boston, MA, USA.
Lisa B WeatherbyOptum Epidemiology, Boston, MA, USA.
Lauren PeetlukOptum Epidemiology, Boston, MA, USA.
An-Chi LoAcumen, LLC, Burlingame, CA, USA.
Kathryn MatuskaAcumen, LLC, Burlingame, CA, USA.
Michael WerneckeAcumen, LLC, Burlingame, CA, USA.
Christine L BuiRTI Health Solutions, 3040 East Cornwallis Rd, PO Box 12194, Research Triangle Park, NC, 27709, USA.
Tainya C ClarkeUS Food and Drug Administration, Silver Spring, MD, USA.
Sylvia ChoUS Food and Drug Administration, Silver Spring, MD, USA.
Elizabeth J BellOptum Epidemiology, Boston, MA, USA.
Grace YangOptum Serve, Falls Church, VA, USA.
Kandace L AmendOptum Epidemiology, Boston, MA, USA.
Richard A ForsheeUS Food and Drug Administration, Silver Spring, MD, USA.
Steven A AndersonUS Food and Drug Administration, Silver Spring, MD, USA.
Cheryl N McMahill-WalravenCVS Health, Blue Bell, PA, USA.
Yoganand ChillarigeAcumen, LLC, Burlingame, CA, USA.
Mary S AnthonyRTI Health Solutions, 3040 East Cornwallis Rd, PO Box 12194, Research Triangle Park, NC, 27709, USA.
John D SeegerOptum Epidemiology, Boston, MA, USA.
Azadeh Shoaibi *US Food and Drug Administration, Silver Spring, MD, USA.
United States Food and Drug Administration · USOptum (United States) · USAcumen (United States) · USNew England College of Optometry · USRTI Health Solutions · USCVS Health (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. This study's objective was to estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children.

methodsThis cohort study identified children aged 5-17 years vaccinated with BNT162b2 matched with unvaccinated children. Participants and BNT162b2 vaccinations were identified in Optum and CVS Health insurance administrative claims databases linked with Immunization Information System (IIS) COVID-19 vaccination records from 16 US jurisdictions between December 11, 2020, and May 31, 2022 (end date varied by database and IIS). Vaccinated children were followed from their first BNT162b2 dose and matched to unvaccinated children on calendar date, US county of residence, and demographic and clinical factors. Censoring occurred if vaccinated children failed to receive a timely dose 2 or if unvaccinated children received any dose. Two COVID-19 outcome definitions were evaluated: COVID-19 diagnosis in any medical setting and COVID-19 diagnosis in hospitals/emergency departments (EDs). Propensity score-weighted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox proportional hazards models, and vaccine effectiveness (VE) was estimated as 1 minus HR. VE was estimated overall, within age subgroups, and within variant-specific eras. Sensitivity, negative control, and quantitative bias analyses evaluated various potential biases.

resultsThere were 453,655 eligible vaccinated children one-to-one matched to unvaccinated comparators (mean age 12 years; 50% female). COVID-19 hospitalizations/ED visits were rare in children, regardless of vaccination status (Optum, 41.2 per 10,000 person-years; CVS Health, 44.1 per 10,000 person-years). Overall, vaccination was associated with reduced incidence of any medically diagnosed COVID-19 (meta-analyzed VE = 38% [95% CI, 36-40%]) and hospital/ED-diagnosed COVID-19 (meta-analyzed VE = 61% [95% CI, 56-65%]). VE estimates were lowest among children 5-11 years and during the Omicron-variant era.

conclusionsReceipt of a complete BNT162b2 vaccine primary series was associated with overall reduced medically diagnosed COVID-19 and hospital/ED-diagnosed COVID-19 in children; observed VE estimates differed by age group and variant era. REGISTRATION: The study protocol was publicly posted on the BEST Initiative website ( https://bestinitiative.org/wp-content/uploads/2022/03/C19-VX-Effectiveness-Protocol_2022_508.pdf ).

Indexed as

BNT162 VaccineCOVID-19Vaccine EfficacyAdolescentChildChild, PreschoolCohort StudiesCOVID-19 VaccinesFemaleHumansMaleSARS-CoV-2United StatesVaccinationBNT162 VaccineCOVID-19 VaccinesCOVID-19 vaccinesEpidemiologyVaccine effectiveness

Identifiers

PMID38671379
PMCPMC11047006
OpenAlexW4395667716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.